Tagraíonn pathophysiology ailse próstatach do na meicníochtaí agus na próisis bunúsacha a fhágann go bhforbrófar agus go dtéann an galar ar aghaidh.
Is tumor malignant é ailse próstatach a thagann ó chealla na gland próstatach, atá ina orgán beag, i bhfoirm walnut atá suite faoi bhun an bhlaisteáin i bhfear.
Táirgeann an gland próstata sreabhach seminal, a chothaíonn agus a iompraíonn sperm.
Ní thuigtear cúis chruinn ailse próstatach go hiomlán, ach tá sé ar eolas go bhfuil roinnt fachtóirí a mhéadaíonn an baol a bhaineann leis an galar a fhorbairt.
Áirítear orthu seo aois, stair an teaghlaigh, cinniúint, agus mutations géiniteacha áirithe.
Tá ailse prostata níos coitianta i bhfear níos sine, agus is i bhfear os cionn 65 bliain d'aois a tharlaíonn an chuid is mó de na cásanna.
Ina theannta sin, tá fear a bhfuil stair teaghlaigh de ailse próstatach acu i mbaol níos mó, mar atá fir Afracach-Mheiriceánach agus fir de shliocht Caribbean.
Baineann pathophysiology ailse próstatach le fás agus roinn neamhrialta cealla laistigh den gland próstatach.
D'fhéadfadh sé seo tarlú mar gheall ar athruithe géiniteacha a fhágann go mbíonn ró-fheidhmíocht ag fachtóirí fáis áirithe nó go bhfuil géiní cosanta tumoracha neamhghníomhach.
D'fhéadfadh na mutations seo a bheith mar thoradh ar fhás neamhrialaithe cealla, rud a fhágann go gcruthóidh tumoir.
De réir mar a fhásann an t-easnamh, is féidir leis ionsaí a dhéanamh ar fíocháin agus orgáin in aice láimhe, mar shampla an bolgán, an rectum, agus na nóid lymph in aice láimhe.
I gcásanna áirithe, is féidir le cealla ailse a bhriseadh amach ón bpríomh-tumor agus scaipeadh go codanna eile den chorp tríd an sruth fola nó an córas lymphatic, próiseas ar a dtugtar metastasis.
Nuair a bheidh an ailse scaipthe, d'fhéadfadh sé a bheith níos deacra a chóireáil.
Is féidir le fachtóirí hormónacha, go háirithe an hormón androgen testosterone, tionchar a imirt ar ailse próstatach freisin.
Is féidir le testosterone fás cealla ailse prostata a spreagadh, agus tá sé mar aidhm ag go leor cóireálacha le haghaidh ailse prostata leibhéil an hormóin seo a laghdú nó a éifeachtaí a bhac.
Go hachomair, baineann pathophysiology ailse próstatach le fás agus roinn neamhrialaithe cealla laistigh den gland próstatach, ar féidir le fachtóirí géiniteacha, hormónacha agus comhshaoil tionchar a imirt orthu.
Tá tuiscint ar mheicníochtaí bunúsacha an ghalair ríthábhachtach chun cóireálacha éifeachtacha a fhorbairt agus torthaí a fheabhsú do othair a bhfuil ailse próstatach orthu.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
Diúltú freagrachta: leighis
Cuirtear an suíomh gréasáin seo ar fáil chun críocha oideachais agus faisnéise amháin agus ní sholáthraíonn sé comhairle leighis nó seirbhísí gairmiúla.
Níor cheart an t-eolas a chuirtear ar fáil a úsáid chun fadhb sláinte nó galar a dhiagnóisiú nó a chóireáil, agus ba cheart dóibh siúd atá ag lorg comhairle leighis phearsanta dul i gcomhairle le dochtúir ceadúnaithe.
Tabhair faoi deara le do thoil go bhfuil an líonra néarónach a ghineann freagraí ar na ceisteanna, míchruinn go háirithe nuair a bhaineann sé le hábhar uimhriúil. Mar shampla, líon na ndaoine a ndearnadh diagnóis orthu le galar ar leith.
Déan comhairle do dhochtúir nó do sholáthraí sláinte cáilithe eile i gcónaí maidir le riocht leighis. Ná déan neamhaird ar chomhairle leighis ghairmiúil ná déileáil leis mar gheall ar rud éigin a léigh tú ar an suíomh Gréasáin seo. Má cheapann tú go bhféadfadh éigeandáil leighis a bheith agat, glaoigh ar 911 nó téigh go dtí an seomra éigeandála is gaire láithreach. Ní chruthaíonn an suíomh Gréasáin seo ná a úsáid aon chaidreamh dochtúir-othar. Ní dhéanann BioMedLib ná a chuid fostaithe, ná aon ranníocóir leis an suíomh Gréasáin seo aon ionadaíochtaí, sainráite nó intuigthe, maidir leis an bhfaisnéis a sholáthraítear anseo ná a úsáid.
Diúltú freagrachta: cóipchirt
Soláthraíonn an Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (an DMCA) aisíocaíocht do úinéirí cóipchirt a chreideann go sáraíonn ábhar atá le feiceáil ar an Idirlíon a gcearta faoi dhlí cóipchirt na Stát Aontaithe.
Má chreideann tú go dea-chreidimh go sáraíonn aon ábhar nó ábhar a chuirtear ar fáil i ndáil lenár suíomh Gréasáin nó lenár seirbhísí do chóipcheart, féadfaidh tú (nó do ghníomhaire) fógra a sheoladh chugainn ag iarraidh an t-ábhar nó an t-ábhar a bhaint, nó rochtain air a bhac.
Ní mór fógraí a sheoladh i scríbhinn trí ríomhphost (féach an rannán "Contact" le haghaidh seoladh ríomhphoist).
Éilíonn an DMCA go gcuimsíonn do fhógra faoi shárú cóipchirt líomhain an fhaisnéis seo a leanas: (1) cur síos ar an saothar cóipchirt atá ina ábhar don shárú líomhain; (2) cur síos ar an ábhar líomhain atá ag sárú líomhain agus faisnéis leordhóthanach chun ligean dúinn an t-ábhar a aimsiú; (3) faisnéis teagmhála duit, lena n-áirítear do sheoladh, uimhir theileafóin agus seoladh ríomhphoist; (4) ráiteas uait go bhfuil creideamh maith agat nach bhfuil an t-ábhar ar an mbealach a bhfuil gearán á dhéanamh air údaraithe ag úinéir cóipchirt, nó a ghníomhaire, nó ag oibriú aon dlí;
(5) ráiteas uait, arna shíniú faoi phionós perjury, go bhfuil an t-eolas sa fhógra cruinn agus go bhfuil an t-údarás agat na cóipchearta a éilítear a shárú a fhorfheidhmiú;
agus (6) síntiús fisiciúil nó leictreonach úinéir an chóipchirt nó duine údaraithe chun gníomhú thar ceann úinéir an chóipchirt.
D'fhéadfadh moill a bheith ar phróiseáil do ghearán mura gcuirfidh tú an t-eolas thuas go léir san áireamh.
Cumarsáid
Seol ríomhphost dúinn le haon cheist / moladh le do thoil.
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Timpeall
Úsáideann BioMedLib ríomhairí uathoibrithe (algorithms foghlama meaisín) chun péirí ceisteanna agus freagraí a ghiniúint.
Tosaímid le 35 milliún foilseachán bithleighis de PubMed/Medline. Chomh maith le leathanaigh ghréasáin de RefinedWeb.
